Abstract:Using diverse arylmethyl groups to replace the benzyl moiety of the lead Hsp90 inhibitor 1 (N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-benzyl-1,2,3,4-tetrahydro-3-iso quinolinecarboxamide), thirty four derivatives (10-43) were developed, and exhibited improved Hsp90 inhibitory and antiproliferative activities. SAR analysis indicated that the southeastern aryl substitutions influenced their antiproliferative activities obviously, with the para-pyridyl group (41) outperforming all other substitution patterns. In this regard, compound 41 was selected for further evaluation. CETSA melt and ITDRFCETSA (isothermal dose-response fingerprint) curves for Hsp90α further proved that 41 interacted with intracellular Hsp90α powerfully. Compared with the lead compound 1, docking and MD refinement of the Hsp90α-41 complex revealed a favorable H-bonding interaction between the side-chain of Tyr139 and the pyridine moiety of 41, which is the first time to be used for resorcinol-based Hsp90 inhibitors. With broad-spectral antitumor activity, compound 41 induced time- and dose-dependent growth inhibition and G0/G1 cell cycle arrest on human breast cancer MDA-MB-453 cell line. In addition, flow cytometry and Western blot analyses confirmed that 41 induced apoptosis of human breast cancer MDA-MB-453 cell line. Via degradation of IKKs and suppression of IKKs activity, compound 41 inhibited TNF-α-induced NF-κB activation. The overall properties warrant compound 41 a promising Hsp90 inhibitor and further biological characterizations. This study provides insights into the chemical evolution of Hsp90 inhibitors, and may facilitate the design of next generation Hsp90 inhibitors for the antitumor drug development.

Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles.

A Combined Molecular Modeling Study on a Series of Pyrazole/isoxazole Based Human Hsp90α Inhibitors

A Combined Molecular Modeling Study On A Series Of Pyrazole/Isoxazole Based Human Hsp90 Alpha Inhibitors

Complex structure of human Hsp90 N and a novel small inhibitor FS5

Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs As Competitive Hsp90 Inhibitors Through Shape-Based Similarity Screening.

Discovery of N-pyridoyl-Δ2 -pyrazolines as Hsp90 inhibitors

Novel Tetrahydropyrido[4,3-d]pyrimidines As Potent Inhibitors of Chaperone Heat Shock Protein 90

Structural aspects of triazole derivatives as HSP90 inhibitors for the treatment of cancer: in silico studies

Design, Synthesis and Pharmacological Evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides As Potent Hsp90 Inhibitors.

Insight into the structural and dynamic properties of novel HSP90 inhibitors through DFT calculations and molecular dynamics simulations

Design and Synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides As Novel Hsp90 Inhibitors.

Discovery of Potent N-(isoxazol-5-yl)amides As HSP90 Inhibitors.

Structural Determination of Three Different Series of Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, Molecular Docking and Molecular Dynamics Methods

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Identification And Structure-Activity Studies Of 1,3-Dibenzyl-2-Aryl Imidazolidines As Novel Hsp90 Inhibitors

Structure Insights into Mechanisms of ATP Hydrolysis and the Activation of Human Heat-Shock Protein 90

Discovery and development of heat shock protein 90 inhibitors.

Identification of a New Series of Potent Diphenol HSP90 Inhibitors by Fragment Merging and Structure-Based Optimization

Design, Synthesis, and Biological Evaluation of Truncated Deguelin Derivatives As Hsp90 Inhibitors

Identification and Optimization of Novel Hsp90 Inhibitors with Tetrahydropyrido[4,3-D]pyrimidines Core Through Shape-Based Screening.

Design, Synthesis and Bioevaluation of Inhibitors Targeting HSP90-CDC37 Protein-Protein Interaction Based on a Hydrophobic Core.